Sapablursen clinical trials
Also written ISIS 702843 and IONIS TMPRSS6-Lrx.
How each study uses sapablursen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sapablursen studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Ionis Pharmaceuticals, Inc. (3) · Ono Pharmaceutical Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses sapablursen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)RecruitingPhase 3Ono Pharmaceutical Co., Ltd.NCT07429266Written as Sapablursen
- A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia VeraCompletedPhase 2Ionis Pharmaceuticals, Inc.NCT05143957Written as sapablursen
- Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)TerminatedPhase 2Ionis Pharmaceuticals, Inc.NCT04059406Written as sapablursen
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Healthy VolunteersCompletedPhase 1Ionis Pharmaceuticals, Inc.NCT03165864Written as IONIS TMPRSS6-Lrx
Codes
What other systems call sapablursen · ClinicalTrials.gg INT016385
- UNII (FDA) DXS4HJC32NSAPABLURSENOne source FDA
- NCI Thesaurus C179118SapablursenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | DXS4HJC32N | SAPABLURSEN | One source FDA |
| NCI Thesaurus | C179118 | Sapablursen | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.